CLAIMS

1. Use of a composition comprising a an allogeneic cell population enriched for human STRO-1^{bright} multipotential cells or progeny thereof in the manufacture of a medicament for treating or preventing a disease in a subject arising from degradation and/or inflammation of cartilage by preserving or generating cartilage that is rich in proteoglycans.

2. The use of claim 4 1, wherein the medicament is not for direct administration into the degraded and/or inflamed cartilage.

3. The use of any one of claims 1 to 2, wherein the medicament is in a form suitable for administration to a joint space.

4. The use of claim 3, wherein the joint space is in a knee joint, hip joint, ankle joint, shoulder joint, elbow joint, wrist joint, hand or finger joint or a joint of the foot, or an intervertebral disc joint.

5. The use of claim 3 or claim 4, wherein the medicament is suitable for administration by intra-articular injection.

6. The use of claim 1, wherein the cartilage that is rich in proteoglycan is hyaline cartilage.

7. The use of any one of claims 1 to 6 wherein the disease is tendonitis, back pain, rotary cuff tendon degradation, Carpal tunnel syndrome, DeQuervain's syndrome, degenerative cervical and/or lumbar discs, intersection syndrome, reflex sympathetic dystrophy syndrome (RSDS), stenosing tenosynovitis, epicondylitis, tenosynovitis, thoracic outlet syndrome, ulnar nerve entrapment, radial tunnel syndrome, repetitive strain injury (RSI), osteoarthritis, rheumatoid arthritis, psoriatic arthritis, seronegative arthritis, arthritis associated with inflammatory bowel disease or ankylosing spondylitis and degenerate invertebral disc disorders.

8. The use of any one of claims 1 to 7, wherein the medicament further comprises a chondroprotective agent.

9. The use of claim 8, wherein the chondroprotective agent is hyaluronic acid.

~~10. The use of any one of claims 1-9, wherein the cell population is an allogenic cell population.~~